Journal: bioRxiv

Article Title: Single cell analysis reveals molecular traits of pediatric lymphoma resistant subclones

doi: 10.64898/2026.04.21.719850

Figure Lengend Snippet: Progenitor-like lymphoma cells are potentially chemoresistance: A. Integration of all cancerous pBL single cells. BCR status shown in color. B. Expression level of genes involved/targeted by R-CHOP regiment (killing) or related to chemoresistance (resist) in cancerous pBL single cells samples. C. Integration of all cancerous pTLBL single cells. TCR status shown in color. D. Expression level of genes involved/targeted by CHOP regiment (killing) or related to chemoresistance (resist) in cancerous pTLBL samples. E. (Left) expression correlation between TUBB and other genes in pBL. Top positive (in blue) and negative (in red) correlated genes were highlighted together with MSI2 . (Right) top enriched terms (gene ontology biological process, GOBP; WikiPathway, WikiPath) for top 300 genes negatively correlated with TUBB expression. F. Highlighted gene expression negatively correlated with TUBB . G. Same as E. but for pTLBL. H. Same as in F. but referred to pTLBL cancerous cells. I. Apoptosis assay for Raji, SUP-T1 and Jurkat cell lines upon MSI2 inhibitor treatment. Cells were incubated for 48h at designated concentrations. J. Schematics of NSG xenograft model utilizing Raji cell line. MSI2 inhibitor was administered intratumorally every 2 days starting from day 10. Experiment end point is represented by tumour reaching 1cm3. K. Tumor volume evaluated at each time point. Statistical analysis performed utilizing 2 way Anova - Šídák’s multiple comparisons test (untill D24). L. Percentage of survival with and without MSI2 inhibitor treatment referred to J. , curve comparison analyzed with Logrank (Mantel-Cox) test.

Article Snippet: Raji, Jurkat and SUP-T1 cell lines were cultured with complete RPMI1640 with 5, 10, 20 μM of MSI2 inhibitor (Ro 08-2750, # HY-108466, MedChemExpress) or DMSO (vehicle) for 48h.

Techniques: Expressing, Gene Expression, Apoptosis Assay, Incubation, Comparison

Journal: bioRxiv

Article Title: Development of a recombinant adeno-associated virus vector for human T lymphocyte- and natural killer cell-targeted gene therapy

doi: 10.64898/2026.02.26.707014

Figure Lengend Snippet: Transduction of SupT1 (A) and Jurkat (B) cells with wild-type (wt) and CD7-engineered AAVs of different serotypes (10,000 gc/cell). Shown are relative % GFP-positive cells at 3 dpi compared to corresponding wt AAV serotype (mean ± SD, n=3). Absolute percentage GFP-positive cells are indicated inside the bars. C ) Representative flow cytometry plots of activated human PBMCs transduced with indicated rAAVs (100,000 gc/cell). D) Absolute % GFP-positivity at 3 dpi (mean ± SD, n≥4). Individual values are presented as dots. E) CD7-specificity factor for transduction (10,000 gc/cell) of activated PBMCs at 3 dpi (mean ± SD, n=3). F) Transduction of activated human PBMCs with indicated rAAVs (100,000 gc/cell) and stratification of GFP-positive cells at 3 dpi in CD4 + T, CD8 + T and NK (CD56 + ) cell types (mean ± SD, n≥3; dot colors represent biologically independent human cell samples). G) Transduction of hepatocyte (HuH-7, HepG2) and kidney (HEK293T) cell lines with indicated rAAVs (100.000 gc/cell). Absolute % GFP-positive cells at 3 dpi (mean ± SD, n=3). rAAV Vectors contained the following sequences: AAV6 & AAV2 = self-complementary genome, CAG promoter; AAV9 & AAV6/9 = single stranded genome, SFFV promoter. Mean ± SD, n=3. For all panels statistical analysis utilized unpaired t-test, p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****).

Article Snippet: Suspension cell lines SupT1 (ATCC: CRL-1942) and Jurkat (RRID: CVCL_C831) were maintained in RPMI 1640 (Biozym Scientific) with 10% FCS, 50 U/mL Penicillin and 50 μg/mL Streptomycin (Pan Biotech).

Techniques: Transduction, Flow Cytometry